Salute e Benessere

OrganOx Completes $142 Million Equity Financing Led by HealthQuest Capital

Financing strengthens OrganOx to expand its leadership position in organ technology OrganOx Ltd ., a leading organ medical technology company, successfully completed a $142 million primary and secondary equity financing to accelerate growth opportunities for itsmetra ® platform technology in the large and high growth organ technology global market. The oversubscribed round was led by new investor HealthQuest Capital with support from existing OrganOx investors BGF and Lauxera Capital...
Nasdaq GlobeNewswire
24/02/2025

Alamar Biosciences launches the NULISAqpcr™ Custom Assay Development Kit to…

"The Custom Assay Development Kit is a direct response to the growing demand from researchers eager to harness our cutting-edge NULISA technology to develop high-performance biomarker assays for translational and clinical research," said Yuling Luo, Ph.D., Founder, Chairman, and CEO of Alamar Biosciences. "This launch marks a major milestone in our mission to build a transformative ecosystem to power precision proteomics." "The Custom Assay Development Kit is a direct…
PR Newswire
24/02/2025

SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS™ FIRST-IN-HUMAN STUDY

Primary safety endpoint met - No serious adverse events reported over 3-months Robust device performance - No device failure reported over 3-monthsSynergia Medical announces that its NAO.VNS™ device, successfully implanted in five patients at UZ Gent and Cliniques universitaires Saint-Luc in Belgium, has met the primary safety endpoint in the AURORA first-in-human clinical study. Synergia Medical's technology is a next-generation neuromodulation platform that eliminates the main metal...
Nasdaq GlobeNewswire
24/02/2025

LabConnect and Australian Clinical Labs' Specialised Trials Announce Strategic…

ACL Specialised Trials is one of the leading clinical trials laboratories in Australia, managing large biotech and pharmaceutical clinical trials from Phase 1 to Phase 4 studies. With a vast network of laboratories across Australia, ACL Specialised Trials has extensive experience in delivering end to end pathology solutions and a wide range of clinical trials central laboratory services for national, multi-site and single site clinical trial studies. ACL Specialised Trials is one of the...
PR Newswire
24/02/2025

TFS HealthScience Announces Leadership Transition: Katarina Ageborg Appointed…

Markus Granlund, a seasoned executive with extensive experience leading international operations, has served as a TFS Board member since October 2024 and previously spent 16 years at Semcon, including 13 years as CEO. His expertise in managing global teams, driving operational excellence, and fostering client-focused partnerships will ensure a seamless transition while reinforcing TFS's commitment to high-quality service and innovation. His appointment follows the leadership announcement shared…
PR Newswire
24/02/2025

Acurx Announces Publication of Positive Results from an In-Silico Study…

Acurx's Executive Chairman, Bob DeLuccia, stated: "This in silico genomic analysis complements the structural biology data emerging from our scientific collaboration with Leiden University Medical Center." He further stated: "We're confident that these results can be leveraged to advance not only the ibezapolstat program but also our systemic Gram-positive antibiotic discovery program in lead optimization for an oral pol IIIC inhibitor for methicillin-resistant Staphylococcus…
PR Newswire
24/02/2025

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and…

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the full year 2024, after U.S. markets close on Wednesday, March 26, 2024. Following the release, Alvotech will conduct a conference call for analysts on Thursday, March 27, 2025, at 8:00 am ET (12 noon GMT). Live audio of the conference call will be webcast and available to members of the...
Nasdaq GlobeNewswire
24/02/2025

Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic…

Despite advancements in oncology, more than 82% of patients with advanced metastatic cancer ultimately succumb to their disease. Current immunotherapies provide only limited survival benefits due to challenges such as T cell exhaustion, inadequate cell numbers, and limited antigen diversity. Swarm's breakthrough T cell therapy platform, Swarm-T, integrates in vivo immune priming with proprietary ex vivo manufacturing to generate highly potent, non-exhausted, polyclonal T cells. Unlike…
PR Newswire
24/02/2025

HKBU receives resounding support from Nobel Laureate and field experts in new…

The meeting was also joined by HKBU's senior management members, including Professor Aiping Lyu, Vice-President (Research and Development) cum Dean of Graduate School and Acting Dean of School of Chinese Medicine; Dr Albert Chau, Vice-President (Teaching and Learning); Ms Christine Chow, Vice-President (Administration) and Secretary; and Professor Terence Lau, Interim Chief Innovation Officer. The meeting was also joined by HKBU's senior management members, including Professor Aiping Lyu,...
PR Newswire
24/02/2025

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and…

MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE)-- BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via...
Nasdaq GlobeNewswire
24/02/2025

Unravelling the infection enigma: Jean-Laurent Casanova's pioneering genetic…

His pioneering work has uncovered more than 70 genes that, when mutated, impair the body's ability to fight off specific infections. This research has not only deepened understanding of human immunity but also led to new possibilities for patient care — helping clinicians better predict, diagnose and treat infectious diseases based on individual genetic profiles. His pioneering work has uncovered more than 70 genes that, when mutated, impair the body's ability to fight off specific infections...
PR Newswire
24/02/2025

Boehringer Ingelheim launches new trivalent poultry vaccine, includes protection…

VAXXITEK ®HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek's disease, Infectious Bursal Disease and H5 avian influenza in just one shot. H5 avian influenza is a highly contagious and notifiable zoonotic disease, that is currently having a heavy impact on the poultry industry, farmers, and international trade worldwide. Administration at the hatchery secures early protection for chicks. With VAXXITEK ®HVT+IBD+H5 , Boehringer...
Nasdaq GlobeNewswire
24/02/2025

Vantage Foundation Brings Hope and Support to Patients at National Burn…

Recognising this, Vantage Foundation stepped in to offer financial support, particularly to those in critical conditions. Beyond financial aid, Vantage Foundation's team took the time to personally engage with patients, offering words of encouragement and emotional support. The visit reinforced the foundation's commitment to supporting vulnerable individuals across different age groups, ensuring that those facing hardship receive both material and moral support. Recognising this, Vantage...
PR Newswire
24/02/2025

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

Professor Umberto Malapelle, Chair of the Predictive Molecular Pathology Laboratory at the Department of Public Health of the University Federico II of Naples, Italy and the Scientific Secretary of the International Society of Liquid Biopsy, championed the new applications to support his research on lung and other cancers. ProfessorUmberto Malapelle, Chair of the Predictive Molecular Pathology Laboratory at the Department of Public Health of the University Federico II ofNaples, Italyand...
PR Newswire
24/02/2025

Simbec-Orion and Avance Clinical Consolidates Partnership with Memorandum of…

A Unified, Global Approach to Clinical TrialsBoth Simbec-Orion and Avance Clinical provide comprehensive clinical research services spanning First in Human (Healthy Volunteers and patients) to pivotal Phase III studies. These include Project Management, Clinical Operations, Medical Monitoring, Regulatory Affairs, Data Management, Biostatistics, Quality Assurance, Pharmacovigilance in addition to IMP Management, Central Lab Services. By leveraging their combined capabilities and...
Nasdaq GlobeNewswire
24/02/2025

Olight and Fujifilm unite innovation and creativity

The i1R 2 Pro is one of Olight's most popular keychain flashlights, features a high-performance CSP LED and TIR optic lens for a soft, balanced beam (5–180 lumens). It has a simple twist controls output, while the larger 130mAh battery provides up to 12 hours of runtime. The i1R 2 Pro was recognized with Red Dot and iF Design Awards in 2024. Thei1R 2 Prois one of Olight's most popular keychain flashlights, features a high-performance CSP LED and TIR optic lens for a soft, balanced beam (5–180…
PR Newswire
24/02/2025

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous…

"HAE affects an estimated 1 in 50,000 people worldwide and is often under recognised, under diagnosed and under treated.3 We welcome the swift approval by the EMA on this additional subcutaneous administration option," said Irmgard Andresen, Global Medical Lead HAE at Takeda. "HAE patients 12 years and older now have an additional individualized treatment option available to them." "HAE affects an estimated 1 in 50,000 people worldwide and is often under recognised…
PR Newswire
24/02/2025

NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of…

HG is a rare, debilitating condition of pregnancy, characterized by intractable nausea and uncontrollable vomiting and frequent, serious complicationsAn increase in the hormone GDF15 is believed to be a root cause of nausea and vomiting in HGNGM Bio is a pioneer and long-time leader in elucidating GDF15 biology, including discovering GDF15's cognate receptor GFRALNGM120, a monoclonal antibody, is designed to block GDF15 activity by binding to GFRAL SOUTH SAN FRANCISCO, Calif., Feb...
Nasdaq GlobeNewswire
24/02/2025

Enhancing radiology workflows: Sectra and Siemens Healthineers enable seamless…

The NAEOTOM Alpha class photon-counting CT scanners create contrast-rich images with high spatial resolution at a lower radiation dose. This is especially beneficial for cases where visualization of fine details and different tissue types is of high importance, such as in imaging of the brain or heart, or in cases where the radiation dose from repeated imaging is a concern, such as in children's cancer care.However, to date, the wealth of spectral information contained in these images could only…
PR Newswire
24/02/2025

Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid…

The data are presented in a poster: CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN-edited allogeneic CAR T-cells without associated IL-2 toxicityPresenter:Shipra Das, Ph.D., Associate Director Immuno-Oncology, at Cellectis. Date/Time:February 25, 2025, 1:45-4:45 p.m. PT Session : Poster Session B CAR T-cell therapies have transformed the treatment landscape for specific hematological malignancies...
Nasdaq GlobeNewswire
24/02/2025

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb…

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitisat the 20 thCongress of ECCO Lusvertikimab achieved statistical significance on the primary and secondary endpointsin moderate to severe active ulcerative colitis (UC) patients during the 10-week induction period of treatment in the randomized, double-blind CoTikiS Phase 2 study. These results were presented in the Top 10 congress highlights oral plenary session...
Nasdaq GlobeNewswire
24/02/2025

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic arthritisMeeting a variety of patient needs, Pyzchiva® offers full suite of dosing options and extended stability compared...
Nasdaq GlobeNewswire
24/02/2025

Telix's Illuccix® PSMA-PET Imaging Agent Approved in Norway

PSMA-PET imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT[4] scan) thereby offering a new standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[5]. Illuccix® PSMA-PET will help fulfil a critical unmet need by…
PR Newswire
24/02/2025

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential…

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's diseaseNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological-endoscopic mucosal improvementFindings to form the basis for a phase 3 program, anticipated to start in H2 2025 Paris and Parsippany,...
Nasdaq GlobeNewswire
22/02/2025
Altri  Comunicati